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Abstract Parkinson’s disease (PD) and dementia with
Lewy bodies (DLB) are usually associated with loss of
dopaminergic neurons. Loss of substantia nigra neurons
and presence of Lewy body inclusions in some of the
remaining neurons are the hallmark pathology seen in the
final stages of the disease. Attempts to correlate Lewy body
pathology to either cell death or severity of clinical
symptoms, however, have not been successful. While the
pathophysiology of the neurodegenerative process can
hardly be explained by Lewy bodies, the clinical symptoms
do indicate a degenerative process located at the presyn-
apse resulting in a neurotransmitter deficiency. Recently it
was shown that 90% or even more of a-synuclein aggre-
gates in DLB cases were located at the presynapses in the
form of very small deposits. In parallel, dendritic spines are
retracted, whereas the presynapses are relatively preserved,
suggesting a neurotransmitter deprivation. The same
a-synuclein pathology can be demonstrated for PD. These
findings give rise to the notion that not cell death but rather
a-synuclein aggregate-related synaptic dysfunction causes
the neurodegeneration. This opens new perspectives for
understanding PD and DLB. If presynaptic a-synuclein
aggregation, not neuronal loss, is the key issue of the
neurodegenerative process, then PD and DLB may even-
tually be treatable in the future. The disease may progress
via trans-synaptical spread, suggesting that stem cell
transplants are of limited use. Future therapies may focus
on the regeneration of synapses.
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Introduction
Synuclein proteins were identified independently by differ-
ent groups. In 1988 Maroteaux et al. [93] described a protein
associated with cholinergic vesicles in the electric organ of
the Pacific electric ray (Torpedo californica) and a related
140 amino acid sequence in a rat brain cDNA library. Based
on the initial findings of its synaptic and nuclear localization,
the protein was denominated by the acronym ‘synuclein’.
Nakajo et al. and George et al. [39, 108] found brain-specific
proteins in bovines and songbirds, and Ueda et al. [139]
identified a 35 amino acid, non-A-b peptide in amyloid
preparations of Alzheimer’s disease patients that belongs to a
140 amino acid protein. Jakes et al. [59] demonstrated the
similarities of these proteins by cloning two human homo-
logues named a and b synuclein. Later, additional sequences
were identified in rats and humans [1, 65] which are more
closely related to the original Torpedo synuclein sequence
and called c-synuclein [22]. Gamma-synuclein was identi-
fied as being equivalent to the breast cancer-specific gene 1
(BCSG1) that is overexpressed in breast cancer cDNA [65].
For the field of neurodegenerative diseases, not only was the
identification of synuclein as a non-A-b component in some
Alzheimer’s cases a milestone, but also the detection of
a-synuclein as the major component of Lewy bodies [6, 128].
The discovery of mutations in the a-synuclein gene [77, 114,
156] and overexpression of a-synuclein [123] as being
associated with Parkinson’s disease or dementia with Lewy
bodies (DLB) strengthens the association between protein
misfolding and disease.
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Although an intranuclear localization was reported ini-
tially, it was not confirmed any earlier than the discovery
that nuclear inclusions in multiple system atrophy (MSA)
are composed of a-synuclein [36, 127, 138, 140, 142].
Meanwhile, physiological a-synuclein can be identified in
neurons [152]. It is upregulated in early-stage neuronal
development [157], binds to histones [42] and affects
histone acetylation [70]. In cell culture experiments, the
C-terminal domain directs recombinant a-synuclein into
the nuclear compartment, whereas presynaptic targeting
depends on the presence of its N-terminal and core region
[126]. The presynaptic localization was reported as early as
the detection of the protein and confirmed by many groups
[57, 59, 107, 137, 150]. Alpha-synuclein was shown to be
related to phospholipids [108] and an interaction with the
presynaptic membrane was reported [20, 34, 66]. Alpha-
synuclein seems to be important for the size of the pre-
synaptic vesicular pool and vesicle recycling [18, 19, 105]
and plays an important role in neurotransmitter release [31,
90], especially for dopamine [2, 33, 91, 122, 151].
Lewy bodies in the pathophysiology of disease
Currently the neuropathological diagnosis of Parkinson’s
disease and dementia with Lewy bodies is based on the
detection and quantification of Lewy bodies [8, 9, 38, 97–
99]. These are insoluble protein aggregates forming fibrils
and composed mainly but not exclusively of a-synuclein
(Fig. 1a, b) [6, 141]. In Parkinson’s disease, Lewy bodies
are mainly found at predilection sites of neuronal loss, i.e.
the substantia nigra and locus coeruleus. This has led to the
conclusion that Lewy bodies are somehow related to nerve
cell loss. The number of Lewy bodies in patients with mild
to moderate loss of neurons in the substantia nigra is higher
than in patients with severe neuronal depletion. It was thus
interpreted that Lewy body-containing neurons are the
dying neurons [141]. On the other hand, Lewy bodies may
not always accompany nerve cell degeneration and it is
indeed unlikely that every dying nerve cell goes through a
stage of Lewy body formation [32]. It was shown that the
presence of Lewy bodies does not predispose substantia
nigra neurons to undergo apoptotic cell death to a greater
degree than the general population of substantia nigra
neurons and most neurons that undergo cell death do not
contain Lewy bodies [136]. Substantia nigra neurons,
whether they contain Lewy bodies or not, are similarly
affected, for example, by morphological dendritic abnor-
malities or biochemical changes, indicating that the
neurons in general are involved in the disease process [11,
52, 61, 113].
Consequently, attempts to correlate the density of either
cortical or brain stem Lewy bodies with clinical disease
symptoms in Parkinson’s disease and DLB were not suc-
cessful. Most studies failed to correlate Lewy body density
with disease duration, early onset, different symptoms at
onset, presence or absence of cognitive fluctuations, visual
hallucinations, delusions, recurrent falls, severity of par-
kinsonism or cognitive decline [43–45, 94, 144]. However,
one study showed a weak correlation between the density
of Lewy bodies in the cingulate gyrus and cognitive decline
[94]. It could be demonstrated that the presence of symp-
toms may be related to the involvement of defined regions
as measured by the occurrence of Lewy bodies [47–49],
supporting the observations that the a-synuclein aggrega-
tion pathology spreads through the brain involving
anatomical structures sequentially [13]. Interestingly, in a
percentage of Parkinson’s patients who developed
dementia, no Lewy bodies could be detected in cortical
areas or in other areas outside the brain stem [37, 87].
These findings indicate that other mechanisms of disease-
spread may exist than is reflected by the development of
Lewy bodies.
The incidence of Lewy bodies in brains of asymptomatic
individuals increases with advanced age. This raises the
question of whether Lewy bodies reflect presymptomatic
Parkinson’s disease, as proposed by Dickson et al. [29], or
are a feature of normal aging [63]. In a series of 904
autopsies, Lewy bodies were found in 106 individuals but
only 32 had been diagnosed as suffering from a neurode-
generative disease [112]. Gibb [41] found an age-
dependent increase in the prevalence of Lewy bodies from
3.8 to 12.8% between the sixth and ninth decade of age,
exceeding the prevalence of age-related Parkinson’s dis-
ease by about 3- to 6-fold, and many other studies show
similar findings (for review see [64]).
In conclusion, although Lewy bodies are the neuro-
pathological hallmark of the diagnosis, the pathophysiology
of the neurodegenerative process can hardly be explained
by them since the number of Lewy bodies is far too low for
the severe symptoms. They appear to be neither associated
with the cell loss nor do they correlate with the severity of
clinical symptoms. Robert D. Terry [131], who did a lot of
work explaining neurodegenerative diseases by synaptic
failure, resumed: ‘‘It seems that not the a-synuclein of the
Lewy body (…) is fatal to the neuron. We had better look
elsewhere in that regard.’’
Synaptic pathology in neurodegenerative diseases
Alzheimer’s disease and prion diseases
In Alzheimer’s disease, the discussion on the impact of the
large Ab aggregates in the form of plaques on the clinical
disease course has lasted for decades. Although there is an
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association between the frequency and extension of tangles
and Ab-plaques and the occurrence of the disease [55,
104], Terry et al. [132] have shown that the cognitive
decline in AD patients only correlates weakly with the
quantity of Ab-plaques or that of neurofibrillary tangles,
but it does correlate with synapse loss detected post-
mortem. Moreover, the synapse loss precedes the cortical
neuron loss. A quantitative morphometric analysis of
temporal and frontal cortical biopsies in AD patients
revealed a greater loss of synapses than of neurons. On
average, 30–38% fewer synapses per surviving neuron
were detected in the temporal cortex in patients 3.4 years
after onset of the disease and 16% fewer synapses in the
frontal cortex 2.3 years after onset [25]. It was assumed
that the cognitive impairment in AD is related to a synaptic
failure [121, 124, 130]. In prion diseases the synaptic
pathology is evident. Kitamoto et al. [68] have shown the
parallels in distribution of prion aggregates and synapto-
physin. This results in a loss of presynaptic terminals
followed by synaptic spine degeneration [10, 62]. The
presynaptic prion protein aggregate deposition could be
linked to the decrease of neurotransmitter release [12].
Obviously, the most aggressive form of prion deposits is
linked to the very faint synaptic aggregates. Whereas
patients who suffer from prion diseases that form plaques
survive for several years, as it is seen in hereditary Gerst-
mann–Stra¨ussler–Scheinker syndrome or associated with
stop mutations [40, 74], the youngest patients seen with
prion diseases die after a much shorter clinical disease
course and exhibit synaptic prion protein deposits that
frequently can be visualized only by using the very sensi-
tive PET blot technique [101, 120].
Evidence for synaptic pathology in Parkinson’s disease
and DLB
The clinical symptoms in Parkinson’s disease and dementia
with Lewy bodies suggest that a failure of synapses is the
pathophysiological mechanism of disease. Tremor at rest,
rigidity, akinesia/bradykinesia and postural instability are
the four cardinal features in Parkinson’s disease [60]. In
DLB, progressive dementia with deficits in attention and
executive functions, fluctuating cognition and recurrent
visual hallucinations occur before or concurrently with the
parkinsonian syndrome [96]. Akinesia/bradykinesia is
assumed to be the result of a disruption of motor cortex
activity (for review see [60]); tremor and rigidity are
related to nigrostriatal dopaminergic deficits and the
dopamine replacement treatment was the major break-
through for Parkinson’s disease patients in the last century
[53]. In DLB and PDD, extrastriatal dopaminergic and
particularly cholinergic deficits play a central role in
mediating dementia (for review see [96]). Various studies
of in vivo imaging of synaptic functions of the CNS found
compelling evidence for presynaptic neurotransmitter
deficiencies in Parkinson’s disease, PDD and DLB (over-
view by [110]). All of these findings indicate that in PD,
PDD and DLB the degenerative process is located at the
presynapse [88] and results in a neurotransmitter deficiency
syndrome.
Synuclein aggregate-related pathology at the synapse
PET blot results
By drawing parallels between a-synuclein aggregation
diseases and prion diseases, we assumed that the synaptic
pathology in Parkinson’s disease and DLB could be linked
to a-synuclein aggregates at synapses. To prove this
hypothesis we used the PET blot method that we ourselves
developed. For the protein aggregate detection by PET blot,
paraffin-embedded tissues were cut the same way as for
conventional histology but the slides were placed onto a
nitrocellulose membrane. By protease digestion, protein
aggregates were mobilized from the tissue, bound to the
nitrocellulose membrane and epitopes in the aggregates
were demasked. An additional guanidine isothiocyanate
pretreatment may enhance the immunoreaction. The pro-
teins were detected by an antibody reaction using the
formazan reaction for visualization [120]. This method is
the most sensitive topographical detection method for pro-
tein aggregates [120] and is widely used in prion research
for this purpose [116, 119, 120, 146], as well as to char-
acterize lesion patterns in humans and animals [85, 95, 135,
145] and to detect extracerebral involvement [3, 78, 133,
134]. Indeed we were able to visualize a significant amount
of tiny a-synuclein aggregates throughout the cortex of
DLB patients using the PET blot method (Fig. 2). These
aggregates appear to be orders of magnitude smaller than
Lewy bodies. The aggregates were most dense in the cin-
gulate cortex. The amount of fine a-synuclein aggregates
exceeds that of Lewy bodies or Lewy neurites by more than
one order of magnitude. The distribution of these aggre-
gates is identical with that of synaptophysin as can well be
demonstrated by immunohistochemistry, suggesting a
synaptic localization of the small a-synuclein aggregates.
This is in keeping with many prion disease cases and fits
well with our initial hypothesis that the synaptic pathology
in DLB is linked to a-synuclein aggregates. Synaptic
a-synuclein aggregates can be visualized by the PET blot
technique also in cortical areas of PDD and brain stem areas
of Parkinson’s disease patients (Fig. 3).
Why was this significant amount of tiny a-synuclein
aggregates not detected earlier? With regular immunohis-
tochemical methods it is not possible to differentiate
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between physiological a-synuclein at the synapses and the
tiny aggregates (Fig. 1b, d). In contrast to prion diseases,
where neuropathologists have in principle the same prob-
lem, the amount of physiological a-synuclein is so high that
staining occurs in all gray matter areas and the aggregates
are so small that they are not easily distinguishable from the
physiological staining (Fig. 1d). Because aggregates have
been shown to contain phosphorylated a-synuclein [35],
antibodies that specifically recognize the Ser129 phos-
phorylation site are able to recognize aggregates that do not
co-react with physiological a-synuclein [117]. This immu-
nohistochemical pattern (see Fig. 1c), however, differs
from that seen with the PET blot (Fig. 2d). In our experi-
ence, only a limited amount of tiny a-synuclein aggregates
is phosphorylated, as shown by PET blot in Fig. 2d
(phosphorylated a-synuclein aggregates) in comparison to
Fig. 2c (all a-synuclein aggregates), whereas all Lewy
bodies can be labelled with both antibodies.
Biochemical analyses
Although the distribution of the small a-synuclein aggre-
gates shows striking similarities to synaptophysin, this does
not predicate where at the synapse the aggregates are
located. To address this question we used a protocol for
subcellular fractionation and synaptosome preparation
from autopsy tissues in combination with a protocol for the
separation of Lewy bodies on the basis of sucrose gradients
Fig. 1 Detection of a-synuclein
deposits in DLB with
conventional methods. H&E (a)
shows 3 Lewy bodies (arrows).
Immunohistochemically, Lewy
bodies are detectable (b),
whereas in the neuropil
a-synuclein deposits are not
distinguishable from the
physiological a-synuclein
staining (d) as compared to a
control case (mAB 4B12,
1:1,000, abcam). With an
antibody against phosphorylated
a-synuclein (c), more deposits
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[50, 58]. The main problem to solve was how to analyse the
gradient fractions to gain information about their a-syn-
uclein aggregate content. In contrast to prions, a-synuclein
aggregates, independent of the disease in which they occur,
are known to be highly insoluble [103], resulting in a smear
at higher molecular weights in Western blot analysis, even
after extraction with guanidinium hydrochloride, urea or
formic acid [6, 67, 82, 89]. Even with the harshest pre-
treatment, the majority of aggregates get stuck at the
bottom of the loading pocket of the gel for electrophoretic
separation. Thus with Western blot a quantification of
a-synuclein aggregate content is impossible [75].
We solved the problem by using a protein aggregate
filtration (PAF) assay. Based on previously described
methods [143, 149], the sucrose gradient fractions were
sucked through a 200-nm-pore-size membrane, and the
aggregates were retained and separated from soluble
a-synuclein [75]. Undesirable binding of soluble proteins
to the membrane was blocked with an amphiphilic polymer
[51]. With this method it was possible to detect a-synuclein
aggregates reliably and most sensitively and to quantify the
amount of aggregates, as shown in dilution series [75].
As a result of the subcellular fractionation we found
three peaks of a-synuclein aggregates. The smallest rep-
resented the Lewy body fraction containing 0.02–11% of
the amount of a-synuclein aggregates. The largest fraction,
corresponding to 50–92% of a-synuclein aggregates, ran at
the 1.0/1.2 M sucrose interface, known for collecting the
Fig. 2 More than 90% of
a-synuclein aggregates are
located outside of Lewy bodies
at synapses in the frontal cortex
of DLB. Frontal cortex and
cingulate gyrus of a DLB- and
control patient as seen using a
dissection microscope (a, b).
The higher magnification of the
PET blot (c) shows the synaptic
distribution of aggregates much
smaller than Lewy bodies (LB
indicated by arrows; mAB
4B12, 1:10,000). Using an
antibody against phosphorylated
a-synuclein (d), only a fraction
of proteinase K-resistant
aggregates is detectable
(polyAB pSer129, 1:5,000). The
detectability of phosphorylated
a-synuclein is strongly
influenced by the fixation
period. Here the tissue was
fixated short term using
buffered formaldehyde.
Bar 100 lm
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synaptosomes [50] that are detached synapses [147].
Indeed, exclusively in this fraction we found the synaptic
vesicle marker synaptophysin and the synaptic membrane
marker syntaxin [76] and identified the synaptosomes by
electron microscopy. To confirm the presynaptic locali-
zation we analysed whether a-synuclein aggregates were
trapped in synaptosomes. By hypertonic lysis, synapto-
somes were disrupted [54] and a-synuclein aggregates
located inside shifted in the sucrose gradient. Indeed, the
a-synuclein aggregates shifted so that only one peak
besides the Lewy body fraction was observed after
hypotonic lysis of the synaptosomes. Analysing the
sucrose gradient fractions by Western blot, it was shown
that the synaptic vesicle protein syntaxin moved with the
a-synuclein aggregates to the higher molecular interface,
whereas the synaptic membrane protein synaptophysin
was found at lower molecular weight in the sucrose
gradient [76]. Moreover, the a-synuclein aggregates that
were not migrating with the Lewy body fraction were one
to two orders of magnitude smaller in size than the Lewy
bodies.
In conclusion, the results from the biochemical analyses
confirmed what we have seen with the PET blot method.
With a magnitude of 1–2 orders more than Lewy bodies, by
far most of the a-synuclein aggregates have the form of
much smaller aggregates than Lewy bodies and they are
located at the presynapse of neurons. In contrast to oligo-
meres, these aggregates are detergent insoluble as was
shown with the aggregate filtration assay and also pro-
teinase K-resistant as shown with the PET blot.
Fig. 3 Synaptic a-synuclein
aggregates are the main
synuclein pathology in
Parkinson’s disease as seen in
DLB. The substantia nigra
shows several proteinase
K-resistant a-synuclein
aggregates besides Lewy bodies
(a). In a Parkinson’s disease
patient with dementia (b), the
frontal cortex shows a lot of tiny
a-synuclein aggregates even
though no Lewy bodies are
detectable (mAB 4B12,
1:10,000). Bar 100 lm
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Do oligomeres or protofibrils explain
the neurodegeneration?
The next question is whether small aggregates might be of
relevance for the pathophysiology of the neurodegenerative
process. In the past, many hypotheses related to small
aggregates in neurodegenerative diseases have been gen-
erated. Because of the problems of small aggregate
detection, it is more common to deal with soluble ‘‘oligo-
meres’’ that can be analysed by Western blot instead of
investigating aggregates that are insoluble. The future will
show whether this research approach advances neurosci-
ence or is misleading. Even most of the research
hypotheses dealing with small aggregates aim to elucidate
the pathways leading to cell death. Because attempts to
explain cell death by detectable fibrillar aggregates failed,
the toxicity of intermediates was suggested [81]. Using in
vitro fibrillogenesis, an oligomerisation of a-synuclein was
found in tissue preparations of patients [23, 80]. These
protofibrils, enriched in b-sheet structure, form spherical
structures that can anneal in a linear fashion forming chains
[23] or anneal in circular fashion forming ring structures.
The spherical protofibrils have a higher tendency to bind to
membranes than monomeric a-synuclein or fibrils. In
membranes, the protofibrils can form pore-like structures
and cause membrane permeabilization [30]. The mecha-
nism of cytotoxicity can be reproduced using designed
proteins not associated with clinical diseases, but only
when they were added to cultured cells in their prefibrillar
state [16]. A concentration-dependent cytotoxicity was
described [7], and an increase in free calcium and reactive
oxygen species levels [15], a dysfunction of mitochondria
and different pattern of cell death were found [17].
Mitochondrial dysfunction gained increased relevance
when researchers found that a syndrome nearly identical to
parkinsonism could be induced by 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) intoxication [79]. A
metabolite of MPTP inhibits the mitochondrial complex I
activity that is involved in the electron transport of the
respiratory chain. As a result, mitochondrial ATP production
is reduced. There may be an increase of reactive oxygen
species, free radicals and induction of apoptosis by mito-
chondrial downstream processes, inducing neuronal cell
death. It is assumed that a-synuclein aggregation accelerates
mitochondrial dysfunction (for reviews see [46, 109, 148]).
In summary, it is questionable whether the hypotheses
related to the toxicity of oligomeres or protofibrils address
the key issues leading to neurodegeneration.
The research on oligomeres and protofibrils was aimed
mostly at explaining cell death, although cell death does
not seem to be the cause of neurodegeneration in DLB and
Parkinson’s disease, and is perhaps only an incidental
consequence.
Are the presynaptic a-synuclein aggregates
of pathophysiological relevance?
From neurophysiological studies it is known that the formation
of postsynaptic dendritic spines is associated with presynaptic
activity. Spine shapes are regulated dynamically by synaptic
activity and changes in shape play an important role in syn-
aptic plasticity. Long-term potentiation induces formation of
new dendritic spines and deprivation causes a reduction [106]
(for review see [153]). We assumed that the huge amount of
presynaptic tiny a-synuclein aggregates have a pathological
impact on dendritic spines. Analysing pre- and post-synaptic
markers in DLB cases, we found a 50% reduction of the pre-
synaptic markers synuclein and syntaxin as compared to
controls [76]. This is in line with previous reports showing a
reduction of presynaptic structures in DLB and Parkinson’s
disease [110, 115]. Looking at postsynaptic markers, there is a
decrease in the postsynaptic scaffold protein PSD95 but the
most considerable changes were seen in an almost complete
loss of drebrin [76]. Drebrin is an f-actin-binding postsynaptic
protein that is known to be involved in organizing the dendritic
pool of actin for the formation of spines [5]. It is reported to
modulate spine size and its content correlates with the spine
head size [69]. In double transgenic mice serving as an
Alzheimer’s disease model (APP- and presenilin-1 mutation),
a drebrin loss in the hippocampus and the entorhinal cortex
precedes the onset of the AD pathology [4].
Because drebrin was beyond the Western blot detection
threshold in frontal cortex samples of all DLB cases, we
were interested in spine morphology. A Golgy–Cox silver
impregnation with modifications according to Davenport was
used [24, 118]. By visualizing the dendritic tree of single cells,
we observed a nearly complete loss of dendritic spines in
frontal cortical neurons of DLB patients, whereas in age-
matched controls the dendrites were densely packed by spines
(Fig. 4). A reduction of dendritic spines has been reported
before in medium spiny neurons of the caudate nucleus in
DLB patients [154]. Similar reports of a selective reduction of
dendritic spines in Parkinson’s disease suggest that the same
pathophysiological changes at the synapse underlie Parkin-
son’s disease as was shown for DLB. Selective loss of
dendritic spines were reported for neurons of the prefrontal
cortex and basal ganglia using the 6-hydroxy dopamine model
for Parkinson’s disease [56, 125] or in reserpine-treated mice
[26] and for striatal regions and the substantia nigra in human
Parkinson’s disease tissues [28, 100, 113, 129, 155].
Detection of synaptic a-synuclein aggregates raises
a novel concept of neurodegeneration
Our result of virtually complete dendritic spine loss in
frontal cortex neurons was surprising because the loss of
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dendritic spines in diseased patients diverges from the
moderate reduction of presynaptic markers. Together with
the notion that nerve cell death is not the key in the path-
ophysiology of a-synuclein aggregating diseases, our
findings give rise to a novel concept of neurodegeneration.
It seems that a presynaptic accumulation of small a-syn-
uclein aggregates are linked to dendritic spine degeneration.
One possibility is that presynaptic a-synuclein aggregation
interferes with neurotransmitter release. It has been shown
in brain slice preparations of C57/Bl6 mice that the deple-
tion of the neurotransmitter dopamine leads to profound
loss of dendritic spines [26]. The imbalance of dendritic
spine changes in relation to the relative preservation of
presynaptic terminals may be explained by the finding that
the bidirectional synaptic plasticity is based on the mor-
phological plasticity of the dendritic spines [106].
The direct link between a-synuclein aggregation and
synaptic pathology paves the way towards explaining the
clinical symptoms of these neurodegenerative diseases. It
serves as a basis for understanding the effect of L-dopa-
therapy at the beginning of symptoms and its failure later in
the disease. Moreover, the observation that a loss of
function of still-existing nerve cells and not nerve cell loss
itself is responsible for the clinical symptoms in DLB,
Parkinson’s disease and PDD makes it conceivable that
these diseases may eventually be treatable in future. An
animated illustration summing up the pathological findings
and building a hypothesis of neurodegeneration based on
presynaptic a-synuclein aggregation can soon be found at
http://www.prionresearch.de.
How does the disease spread?
Many questions still remain to be answered. One of the
most important issues is how the disease progresses.
Neuropathological studies implicate a spread of a-synuc-
lein aggregate pathology [13] because in early stages the
pathological changes are restricted to certain areas that are
constantly involved in later stages. These studies, however,
are of limited use here because they assume Lewy bodies,
rather than synaptic aggregates, to be an equivalent for the
spread of pathology. The pattern of spread shows some
parallels to prion diseases, although an infectivity of
a-synuclein aggregates has not yet been shown. In prion
diseases a trans-synaptic spread is evident [95]. This
pathway can easily be explained because the physiological
prion protein is anchored at the outer surface of nerve cells
and lymphocytes, and prion aggregates can be found extra-
as well as intracellularly. In contrast, a-synuclein is a
cytoplasmatic protein. The mode of spread is an actual
matter of debate. Recent findings that a-synuclein pathol-
ogy spreads to implanted grafts, focused research efforts on
this topic. In three autopsy studies of patients who received
transplants of foetal mesencephalic neurons 11–14 years
earlier, Lewy body-like inclusions reacting with antibodies
against a-synuclein were detected [71, 72, 86]. These
findings suggest that a-synuclein aggregation may spread
from host to graft. The Lewy body-like pathology in
grafted neurons does not necessarily mean their functional
impairment. Our findings of synaptic a-synuclein pathol-
ogy, although not yet shown in grafted neurons, may be
one step towards explaining the graft pathology because
the integration of grafts by synaptic contacts was demon-
strated [73], and a trans-synaptic spread is one possible
explanation. Oligomeres of a-synuclein have been shown
to be released from cultured cells by exocytosis [83], and
can be taken up via endocytosis [84]. Recently a neuron-to-
neuron spread of a-synuclein pathology was shown in a
cell culture model using adenovirus-mediated a-synuclein
overexpression. Additionally, a neuron-to-neuron spread
was demonstrated using cortical neural stem cells that were
implanted into a-synuclein transgenic mice [27]. Other
experiments have shown evidence that the pathological
conformation of a-synuclein may act as a seed for forming
aggregates in target cells [92]. For b-amyloid [102] and tau
[21] seeding effects have been shown to induce the
aggregation of the respective protein in transgenic animal
models. Interestingly, an induction of a-synuclein aggre-
gates into the enteric nervous system by oral application of
Fig. 4 An almost complete loss
of dendritic spines accompanies
the presynaptic a-synuclein
aggregates. Golgy–Cox–
Davenport staining of a
neuronal dendrite of a frontal
cortex neuron in a DLB patient
(a) is compared to a control
patient of the same age (b).
Bar 50 lm
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rotenone, which causes non-detectable levels of the toxin in
blood or brain, was followed by a spread of a-synuclein
pathology to the dorsal motor nucleus of the vagus, the
intermediolateral nucleus in the spinal cord and the sub-
stantia nigra [111]. With these recent findings, a trans-
synaptic spread of a-synuclein pathology seems to be a
more likely explanation for the propagation of the disease
than alternative explanations such as inflammatory pro-
cesses, oxidative stress or loss of neurotrophic support [14].
The latter aspects may be more of interest for explaining
the initiation of the a-synuclein aggregation. They may
also make cells vulnerable to amplify aggregates.
Conclusion
The clinical symptoms suggest that a synaptic dysfunction
is the cause of the neurodegenerative process in Parkin-
son’s disease and dementia with Lewy bodies. The
discovery of a link between these diseases and mutations in
the a-synuclein gene or a synuclein dose–response effect,
respectively, highlight the importance of protein aggrega-
tion-related toxicity as a key issue in neurodegeneration.
The recent finding that 90% or even more of a-synuclein
aggregates are not localized in Lewy bodies but at the
presynapse in the form of much smaller aggregates than
Lewy bodies, may contribute towards explaining the
synaptic dysfunction. In consequence, dendritic spines are
retracted most obviously because of neurotransmitter
deprivation. If synaptic a-synuclein aggregation is indeed
the key issue in PD and DLB, then it is not cell death but a
synaptic dysfunction that causes the neurodegenerative
symptoms. Although synaptic a-synuclein aggregation has
been neither postulated nor demonstrated before, a synaptic
dysfunction has been assumed in explaining neurodegen-
eration for decades. The link between a-synuclein
aggregation and the synaptic pathology opens a completely
new avenue towards understanding these diseases as well
as treatment options. If the presynaptic a-synuclein
aggregation is the key issue, then PD and DLB may
eventually be treatable in future, because the neuronal cells
and their presynapses are, in principle, still present and the
postsynapse is able to regenerate. Seen in the light of these
new findings, therapeutic strategies against nerve cell death
and stem cell implantation strategies may well be obsolete.
As postulated by Terry, it can be assumed that a synaptic
dysfunction in other neurodegenerative diseases such as
Alzheimer’s disease, ALS and Huntington’s disease is
linked to protein aggregates other than plaques or tangles.
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